Table 1 Correlation between the clinicopathologic features and PABPC1 expression in 157 nasopharyngeal carcinoma patients
Characteristics | N | PABPC1 | Statistics (χ2, P value) | EBER1/2 | Statistics (χ2, P value) | ||
|---|---|---|---|---|---|---|---|
Low-expression (%) | High-expression (%) | Low-expression (%) | High-expression (%) | ||||
Gender | |||||||
 Male | 114 | 64 (56.1) | 50 (43.9) | 3.447, 0.075 | 16 (14.0) | 98 (86.0) | 0.000, 0.990 |
 Female | 43 | 17 (39.5) | 26 (60.5) |  | 6 (14.0) | 37 (86.0) | |
Age | |||||||
 ≥ 55 | 71 | 27 (38.0) | 44 (62.0) | 9.549, 0.002** | 6 (8.5) | 65 (91.5) | 3.328, 0.086 |
 < 55 Smoking, Drinking | 86 | 54 (62.8) | 32 (37.2) |  | 16 (18.6) | 70 (81.4) |  |
 Yes | 61 | 32 (52.5) | 29 (47.5) | 0.030, 0.871 | 6 (9.8) | 55 (90.8) | 1.444, 0.229 |
 No | 96 | 49 (51.0) | 47 (49.0) |  | 16 (16.7) | 80 (83.3) | |
WHO classification | |||||||
 Type III | 87 | 45 (51.7) | 42 (48.3) | 1.076, 0.584 | 10 (11.5) | 77 (88.5) | 1.275, 0.529 |
 Type II | 69 | 36 (52.2) | 33 (47.8) |  | 12 (17.4) | 57 (82.6) | |
 Type I | 1 | 0 (0.0) | 1 (100.0) |  | 0 (0.0) | 1 (100.0) | |
Clinical stage | |||||||
 I-II | 36 | 23 (63.9) | 13 (36.1) | 2.828, 0.128 | 2 (5.6) | 34 (94.4) | 2.773, 0.096 |
 III-IV | 121 | 58 (47.9) | 63 (52.1) |  | 20 (16.5) | 101 (83.5) | |
T | |||||||
 T1-2 | 89 | 47 (52.8) | 42 (47.2) | 0.122, 0.750 | 10 (11.2) | 79 (88.8) | 1.315, 0.252 |
 T3-4 | 68 | 34 (50.0) | 34 (50.0) |  | 12 (17.6) | 56 (82.4) | |
N | |||||||
 N0 | 29 | 15 (51.7) | 14 (48.3) | 0.000, 1.000 | 3 (10.3) | 26 (89.7) | 0.397, 0.529 |
 N1-3 | 128 | 66 (51.6) | 62 (48.4) |  | 19 (14.8) | 109 (85.2) | |
M | |||||||
 M0 | 153 | 80 (52.3) | 73 (47.7) | 1.162, 0.355 | 22 (14.4) | 131 (85.6) | 0.669, 0.413 |
 M1 | 4 | 1 (25.0) | 3 (75.0) |  | 0 (0.0) | 4 (100.0) | |
Recurrence | |||||||
 Yes | 44 | 11 (25.0) | 33 (75.0) | 17.310, < 0.001** | 5 (11.4) | 39 (88.7) | 0.356, 0.551 |
 No | 113 | 70 (61.9) | 43 (38.1) |  | 17 (15.0) | 96 (85.0) | |
Treatment | |||||||
 Yes | 120 | 68 (56.3) | 52 (43.7) |  | 19 (15.8) | 101 (84.2) | 1.401, 0.237 |
 No | 37 | 13 (36.8) | 24 (63.2) | 5.250, 0.025* | 3 (8.1) | 34 (91.9) | |
Ki-67 | |||||||
 ≥ 50% | 67 | 36 (53.7) | 31 (46.3) |  | 7 (10.4) | 60 (89.6) | 1.233, 0.267 |
 < 50% | 90 | 45 (50.0) | 45 (50.0) | 0.214, 0.747 | 15 (16.7) | 75 (83.3) | |
P53 | |||||||
 ≥ 50% | 28 | 12 (42.9) | 16 (57.1) |  | 1 (3.6) | 27 (96.4) | 3.083, 0.079 |
 < 50% | 129 | 69 (53.5) | 60 (46.5) | 1.041, 0.405 | 21 (16.3) | 108 (83.7) | |
EBER | |||||||
 ≥ 75% | 135 | 68 (50.4) | 67 (49.6) |  | \ | \ | \ |
 < 75% | 22 | 13 (59.1) | 9 (40.9) | 0.576, 0.497 | \ | \ | |
PABPC1 | |||||||
 ≥ 25% | 76 | \ | \ | \ | 9 (11.8) | 67 (88.2) | 0.576, 0.448 |
 < 25% | 81 | \ | \ |  | 13 (16.0) | 68 (84.0) | |